<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01858935</url>
  </required_header>
  <id_info>
    <org_study_id>ND-L02-s0201-001</org_study_id>
    <nct_id>NCT01858935</nct_id>
  </id_info>
  <brief_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection in Normal Healthy Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ND-L02-s0201 Injection, a Vitamin A-Coupled Lipid Nanoparticle Containing siRNA Against HSP47, in Healthy Normal Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nitto Denko Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, tolerability, and pharmacokinetics of ND-L02-s0201 in&#xD;
      normal, healthy, subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence, nature, and severity of adverse events and abnormal clinical laboratory tests</measure>
    <time_frame>After single-ascending doses</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile and parameters</measure>
    <time_frame>After single-ascending doses</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>ND-L02-s0201 Injection 0.03 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ND-L02-s0201 Injection 0.1 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ND-L02-s0201 Injection 0.2 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ND-L02-s0201 Injection 0.4 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ND-L02-s0201 Injection 0.5 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ND-L02-s0201 Injection 0.6 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ND-L02-s0201 Injection 0.8 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ND-L02-s0201 Injection</intervention_name>
    <description>Single IV infusion.</description>
    <arm_group_label>ND-L02-s0201 Injection 0.03 mg/kg</arm_group_label>
    <arm_group_label>ND-L02-s0201 Injection 0.1 mg/kg</arm_group_label>
    <arm_group_label>ND-L02-s0201 Injection 0.2 mg/kg</arm_group_label>
    <arm_group_label>ND-L02-s0201 Injection 0.4 mg/kg</arm_group_label>
    <arm_group_label>ND-L02-s0201 Injection 0.5 mg/kg</arm_group_label>
    <arm_group_label>ND-L02-s0201 Injection 0.6 mg/kg</arm_group_label>
    <arm_group_label>ND-L02-s0201 Injection 0.8 mg/kg</arm_group_label>
    <other_name>BMS-986263</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single IV infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects aged between 18 and 55 years.&#xD;
&#xD;
          2. Willing and able to comply with the study procedures and visit schedule, including&#xD;
             follow-up visits.&#xD;
&#xD;
          3. Able to communicate effectively with the study site personnel.&#xD;
&#xD;
          4. Body mass index (BMI) within the range of ≥18.5 and ≤30.&#xD;
&#xD;
          5. Determined by the Investigator to be in good health as documented by the following:&#xD;
&#xD;
               1. Medical history;&#xD;
&#xD;
               2. Physical examination (including but not limited to an evaluation of the&#xD;
                  cardiovascular, gastrointestinal, respiratory and central nervous systems);&#xD;
&#xD;
               3. Vital sign assessments: systolic blood pressure ≤140 mmHg, diastolic blood&#xD;
                  pressure ≤90 mmHg, heart rate 45-85 bpm;&#xD;
&#xD;
               4. Normal 12-lead electrocardiogram (ECG): heart rate: 44-85 bpm, PR interval: ≤210&#xD;
                  msec, QRS duration: ≤120 msec, QTcF: ≤430 msec;&#xD;
&#xD;
               5. Clinical laboratory assessments within the laboratory's limits of normal values&#xD;
                  or not considered clinically significant by the Investigator; and&#xD;
&#xD;
               6. By general observations. For any abnormalities or deviations outside the normal&#xD;
                  ranges for any clinical tests (including all laboratory tests, ECG, vital signs),&#xD;
                  the test may be repeated at the discretion of the Investigator, but the results&#xD;
                  must be discussed with the Sponsor's Medical Monitor before being judged to be&#xD;
                  not clinically significant for study participation.&#xD;
&#xD;
          6. Serum calcium, parathyroid hormone, testosterone within the laboratory's limits of&#xD;
             normal values and 25OH-vitamin D ≥18 ng/mL.&#xD;
&#xD;
          7. Non-smoker, defined as no smoking within the 3 months prior to administration of study&#xD;
             drug and urine cotinine &lt; 400 ng/mL.&#xD;
&#xD;
          8. Consumed an average of no more than 2 drinks per day within the 6 months prior to&#xD;
             administration of study drug. A drink is one 12 oz. beer, 4 oz. of wine, 1.5 oz. of&#xD;
             80-proof spirits, or 1 oz. of 100-proof spirits.&#xD;
&#xD;
          9. Subjects with female partners of childbearing potential must agree to use an effective&#xD;
             barrier method of contraception (e.g., condom with spermicide) from study drug&#xD;
             administration until the Day 28 visit. All fertile men with female partners of&#xD;
             childbearing potential should be instructed to contact the Investigator immediately if&#xD;
             they suspect their partner might be pregnant (e.g., missed or late menstrual period)&#xD;
             at any time during study participation.&#xD;
&#xD;
         10. Subjects must give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any disease or condition (medical or surgical) which, in the opinion of the&#xD;
             Investigator, might compromise the hematologic, cardiovascular, pulmonary, renal,&#xD;
             gastrointestinal, hepatic, skeletal, or central nervous system; or other conditions&#xD;
             that may interfere with the absorption, distribution, metabolism or excretion of&#xD;
             ND-L02-s0201, or would place the subject at increased risk.&#xD;
&#xD;
          2. History of bone disease, including osteoporosis and osteomalacia, Paget's disease of&#xD;
             bone, or a history of unexplained fractures or fractures after minimal trauma.&#xD;
&#xD;
          3. The presence of abnormal laboratory values considered to be clinically significant by&#xD;
             the Investigator.&#xD;
&#xD;
          4. Positive screen for Hepatitis B (HBsAg, Hepatitis B Surface Antigen), Hepatitis C&#xD;
             (anti-HCV, Hepatitis C Antibody) or human immunodeficiency virus (HIV) (anti-HIV 1/2).&#xD;
&#xD;
          5. Participating in a concurrent interventional study with the last intervention&#xD;
             occurring within 30 days prior to administration of study drug.&#xD;
&#xD;
          6. Received any drug therapy (including prescription and over-the-counter drugs and&#xD;
             herbal supplements) within 1 week or 5 half-lives (whichever is longer), prior to&#xD;
             administration of study drug. Use of non-steroidal anti-inflammatory drugs (NSAIDs),&#xD;
             sulfonamides, probenecid or other drugs known to alter renal or tubular function is&#xD;
             specifically prohibited for at least 5 half-lives prior to the administration of study&#xD;
             drug. Use of immuno-suppressants is specifically prohibited within 1 week or 5&#xD;
             half-lives (whichever is longer), prior to administration of study drug. Vitamin A&#xD;
             containing multi-vitamins must be withheld from Day -1 through Day 5.&#xD;
&#xD;
          7. Consumption of alcohol within 48 hours prior to administration of study drug or during&#xD;
             the in-patient period.&#xD;
&#xD;
          8. Positive urine screen for drugs of abuse, to include ethanol, cocaine,&#xD;
             tetrahydrocannabinol (THC), barbiturates, amphetamines, benzodiazepines, opiates,&#xD;
             cotinine, and other drugs of abuse in the study site's location.&#xD;
&#xD;
          9. History, within the last 2 years, of alcohol abuse, significant mental illness, or&#xD;
             physical dependence on any opioid.&#xD;
&#xD;
         10. Illicit drug use within the last 90 days.&#xD;
&#xD;
         11. Demonstration, in the opinion of study staff, of veins unsuitable for repeated&#xD;
             venipuncture or intravenous infusion (e.g., veins that are difficult to locate, access&#xD;
             or puncture; veins with a tendency to rupture during or after puncture).&#xD;
&#xD;
         12. Recent treatment with alternative therapies, which, in the opinion of the&#xD;
             Investigator, could potentially confound clinical or laboratory assessments.&#xD;
&#xD;
         13. Donation or loss of more than 500 mL of blood within 56 days prior to administration&#xD;
             of study drug or donation of plasma within 7 days prior to administration of study&#xD;
             drug.&#xD;
&#xD;
         14. History of malignancy within the last 5 years, with the exception of non-facial basal&#xD;
             cell carcinoma.&#xD;
&#xD;
         15. History of severe allergic or anaphylactic reactions.&#xD;
&#xD;
         16. Any other reason that, in the opinion of the Investigator or the Sponsor's Medical&#xD;
             Monitor, makes the subject unsuitable for enrollment.&#xD;
&#xD;
         17. History of hypersensitivity to H2-receptor antagonists.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mathews, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Quintiles Phase One Services, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quintiles Phase One Services, LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <study_first_submitted>May 17, 2013</study_first_submitted>
  <study_first_submitted_qc>May 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2013</study_first_posted>
  <last_update_submitted>May 9, 2017</last_update_submitted>
  <last_update_submitted_qc>May 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

